Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

ViaCyte raises $10mm

Executive Summary

Regenerative medicine firm ViaCyte Inc. raised $10mm in a late-stage financing from Asset Management Partners, WL Gore & Associates, JDRF, and undisclosed current investors. The company will use the funds to commence clinical trials of its PEC-Direct, which treats Type I diabetes by administering stem cell-derived pancreatic progenitor cells in an implantable device. Additional funds will support ongoing development of its PEC-Encap stem cell-derived islet replacement therapy for all diabetics who require insulin to control the disease.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Implantable Devices
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register